Key Points
- CEO Ryan Fukushima sold 14,286 Tempus AI shares at an average price of $70, generating approximately $1.0 million. The Rule 10b5-1 transaction reduced his position by 23.15%, leaving him with 47,420 shares.
- Tempus AI shares were trading at $68.73, up 3.9%, with a market capitalization of about $12.4 billion. The company recently beat quarterly earnings and revenue estimates, reporting $382.5 million in revenue, up 21.6% year over year.
- Analyst sentiment remains mixed, with nine Buy, six Hold, and two Sell ratings; the consensus rating is Hold with an average price target of $65.69. Institutional investors own 24.22% of the company.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Ryan Fukushima sold 14,286 shares of Tempus AI stock in a transaction on Friday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $1,000,020.00. Following the completion of the transaction, the chief executive officer owned 47,420 shares in the company, valued at approximately $3,319,400. This trade represents a 23.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Tuesday, August 18th, Ryan Fukushima sold 41,095 shares of Tempus AI stock. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95.
- On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $50.04, for a total value of $1,000,800.00.
- On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total value of $1,100,153.42.
- On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
- On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.
Tempus AI Trading Up 3.9%
NASDAQ TEM opened at $68.73 on Wednesday. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of -47.73 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The company's 50 day moving average price is $53.57 and its 200 day moving average price is $51.49.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The business's quarterly revenue was up 21.6% on a year-over-year basis. On average, sell-side analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.
Institutional Investors Weigh In On Tempus AI
Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in shares of Tempus AI by 6,379.2% during the second quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company's stock worth $404,189,000 after purchasing an additional 6,869,519 shares during the last quarter. GC Wealth Management RIA LLC bought a new stake in Tempus AI in the fourth quarter valued at about $399,267,000. Voloridge Investment Management LLC raised its stake in Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock valued at $129,708,000 after buying an additional 1,039,176 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Tempus AI during the second quarter valued at approximately $54,020,000. Finally, Sumitomo Mitsui Trust Group Inc. lifted its holdings in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company's stock worth $195,636,000 after buying an additional 821,490 shares during the last quarter. Institutional investors own 24.22% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on TEM shares. TD Cowen reissued a "buy" rating on shares of Tempus AI in a research report on Wednesday, July 15th. Stifel Nicolaus reduced their target price on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a research report on Monday, August 3rd. Guggenheim raised their price target on shares of Tempus AI from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a report on Tuesday, June 30th. Finally, Wall Street Zen upgraded Tempus AI from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $65.69.
View Our Latest Research Report on TEM
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
